Clinical trials: Affective Disorder
Major Depression, Dysthymia
Dichotic Listening as a Predictor of Medication Response in Depression
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
- Conditions
- Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
- Trial name
- NCT00296725
- Testing
- Fluoxetine, Imipramine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder
Short Term Rescue Study of Olanzapine
We will assess the effect of olanzapine compared to placebo added to prior treatment on CGI-S in a one-week randomized double-blind study.
- Trial name
- NCT00186017
- Testing
- Olanzapine/Zyprexa
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Schizophrenia, Schizo Affective Disorder
Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider Engagement
The effective treatment of schizophrenia is very challenging due to a number of factors. These include issues such as poor engagement with treatment plans and care providers, limited contacts with providers due to under-resourced…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- NCT04602741
- Testing
- A4i Intervention
- Where
- Canada
- Volunteers
- 91 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function
The purpose of this study is to understand the effectiveness of a ten-week internet-based cognitive behavioral therapy (iCBT) treatment on improving depressive symptoms, coping and resilience skills, and cognitive processing.
- Trial name
- iCBT (NCT01598922)
- Testing
- Internet Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression
This study was conducted to understand the use of a mobile app (titled Pathway) to help patients track depression symptoms, medications, side effects, and goals in addition to the usual care with their doctor.
- Trial name
- NCT04891224
- Testing
- Pathway Platform mobile app
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Wake Forest University Health Sciences
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bipolar I Disorder, Bipolar II Disorder
Sensoril(Ashwaganhda)for Bipolar Disorder
The investigators hypothesis is that oral Sensoril® (as compared to placebo) will enhance cognitive abilities (specifically measures of attention, executive function, working memory, and visuospatial ability) in persons with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS
- Trial name
- NCT00761761
- Testing
- Sensoril
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Imaging Dopamine Release in Depression
This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict…
- Trial name
- NCT02033369
- Testing
- Pramipexole
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Borderline Personality Disorder
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young…
- Trial name
- NCT01103180
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Major Depressive Disorder
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
- Trial name
- NCT02389816
- Testing
- Vortioxetine
- Where
- 47 sites in Japan
- Volunteers
- 493 people
- Sponsor
- Takeda
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Disorder
Bipolar Transcranial Alternating Current Stimulation (tACS)
The purpose of this clinical trial is to measure the safety and effectiveness of a non-invasive brain stimulation device called Transcranial Alternating Current Stimulation (tACS) in participants with bipolar disorder (BD).
- Trial name
- NCT05480124
- Testing
- tACS brain stimulation treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Michigan
Major Depressive Disorder
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD.
- Trial name
- NCT00644358
- Testing
- vilazodone
- Where
- 38 sites in United States
- Volunteers
- 616 people
- Sponsor
- Forest Laboratories
Tobacco Use Disorder
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions.
- Trial name
- NCT04090879
- Testing
- Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g), E-Cigarettes
- Where
- 2 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Brown University
Bipolar Disorder
3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects
3-week study to evaluate efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects
- Trial name
- NCT00312494
- Testing
- Ziprasidone
- Where
- 66 sites in United States
- Volunteers
- 680 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Mood Disorders
An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder
To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder.
- Trial name
- NCT00579982
- Testing
- Lamotrigine
- Where
- 18 sites in United States
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder
Geodon in Weight Loss Study for Bipolar Disorders
This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight.
- Trial name
- NCT00472641
- Testing
- Ziprasidone/Geodon
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.